TERMIS-EU - Pre-Accelerator Programme 2016/2017 - Session 2: Building an Evidence Base

The second webinar in the 2016/2017 Pre-Accelerator Programme was on how to build an evidence base for achieving regulatory approval and convincing investors.

Go to the profile of Richard Balint
Dec 19, 2016

To provide a strong evidence base for an advanced therapeutic a following must be performed: The proof of concept must be demonstrated both in vitro and in vivo. The safety of each component in the therapeutic must be tested (risk assessment, possible side effects, stability). Efficacy and ideal parameters of each component must be tested. Fundamental research must be performed to understand the underlying science of the proposed mechanism of the therapeutic. A systematic review of scientific literature should be performed. Meta-analyses must be carried out: What kind of proof does your experimental work provide in light of the analysis of the aggregate results in the relevant field? Randomised control trials have to be performed: What is the clinical and pre-clinical scenario for your product/idea? What are the measures to prevent bias?

For more detailed information on the topic please read our medium.com blog: https://medium.com/@TERMISEUBPC/termis-pap-session...

You can also watch the recording of the webinar through: http://termisbpc.org/pap/session-2/

Go to the profile of Richard Balint

Richard Balint

EPSRC Doctoral Prize Fellow at The University of Manchester, The University of Manchester

No comments yet.